In mice given food containing clofibrate (I) [637-07-0] (0.25%) for 3 wk, there was a 3.8 fold increase in the amount of peroxisome-associated mol. weight 80,000 polypeptide in liver; the half-life for degradation of the polypeptide was increased from 32.4 h to 38.4 h.Thus, the increase in the amount of this peptide is primarily due to enhancement of formation of the peptide.The effect of I on some peroxisomal enzymes and enzymes associated with fatty acid metabolism was determinedThe activities of the cyanide-insensitive fatty acyl-CoA oxidation system and carnitine acetyltransferase [9029-90-7] were increased by I.

1975-02-01·Biochemical Medicine

Assay of clofibrate in human serum by gas chromatography

Article

作者: Arthur Karmen ; Harold Haut

A method for assaying clofibrate (I) [637-07-0] in serum based on gas-liquid chromatog. of the Me ester was described.Two internal standards, similar in chem. structure to I (chlorophenoxy acetic and chlorophenoxy propionic acids), are added; the compounds are extracted, converted to Me esters, and analyzed by gas-liquid chromatog. using an alkali flame ionization detector selectively sensitive to halogen.The serum levels of I following a single oral therapeutic dose can be followed conveniently, suggesting the use of the procedure for monitoring adherence to therapy or for studying the metabolism of the drug.

1972-03-01·Biochemical Pharmacology2区 · 医学

Effect in vitro of clofibrate and trans-l,4-bis-(2-chlorobenzylaminoethyl)-cyclohexane dihydrochloride (AY 9944) on respiration and adenosine triphosphatase activity of mouse liver mitochondria

2区 · 医学

Article

作者: S.L. Katyal ; Jon J. Kabara ; J. Saha

The addition of 50 μg clofibrate (I) [637-07-0] to mouse liver mitochondria suspensions in aqueous Na glutamate [142-47-2] solutions resulted in stimulation of state 4 respiration (ADP [58-64-0] limited, substrate and O in excess), but state 3 (excess ADP) was eliminated.Similar responses were obtained by substituting Na α-ketoglutarate [305-72-6] plus Na malonate [23549-97-5] for the Na glutamate, but state 4 respiration was not significantly altered when only the ketoglutarate or the malonate was used.Addition of 400 μg I to a Na succinate [14047-56-4] utilizing system increased the state 4 respiration rate but did not alter the state 3 respiration rate.AY 9944 [trans-1,4-bis[(2-chlorobenzyl)aminomethyl]cyclohexane dihydrochloride] (II) [366-93-8] stimulated the ATPase activity at .leq.100 μg/mg mitochondrial protein) with and without dinitrophenol (II) [51-28-5].Addition of MgCl2 stimulated ATPase at 25-50 μg II/mg mitochondrial protein, but at higher concentrations it decreased the activity as compared to that without Mg2+.I added at 400 μg/mg protein increased the ATPase activity.The effects of addition of III plus I, and of MgCl2 plus I were additive.

项与氯贝酸铝相关的新闻（医药）

2022-09-22

·药通社

100000000销售额眼科特色品种原料首家转A获批且价廉质优！

小编在药融云数据（药融云数据）查询地夸磷索钠滴眼液审评数据时，发现该品种目前在审评中的有10家，通过一致性评价的有3家。经查询原料药地夸磷索钠在CDE原辅包登记信息公示平台状态为A的有广东先强药业有限公司等在内的4家公司，其中广东先强药业有限公司为国内首家通过CDE审评审批结果为“A”的企业。地夸磷索钠原料药首家通过CDE技术审评和GMP符合性是广东先强药业原料药研发能力、生产及质量管理体系等综合实力的体现，是先强药业CDMO转型的重要里程碑。下面跟着小编一起走进广东先强药业.....广东先强药业有限公司简介广东先强药业有限公司成立于2002年，是A股上市公司众生药业（002317）的全资子公司和原料药生产基地，专业从事化学品的CDMO和特色原料药的研产销。公司位于广州黄埔中新知识城北的从化经济开发区（高技术产业园），属粤港澳大湾区核心区域，离广州白云机场20公里，交通便利。公司建有高水平的质量技术中心，匹配原料药全检全套仪器设备，满足注册法规、CFDI核查和国内外客户审计的要求。建有多个原料药多功能车间、高效的污水处理设施和符合国际审计标准的专用仓库，能实现从小试研究、中试放大、注册申报、大规模生产的一条龙服务。核心优势：原料药品种的生产转化和高效注册技术优势：核苷类产品的快速研发业务板块1）原料药CXO服务（化学药和生物药）2）原料药合作研发和关联申报（仿制药和创新药中外双报）3）原料药工艺变更、质量提升服务（补充申请）特色优势1) 小批量树脂纯化及高端膜过滤生产革新技术2) 大盘冻干及绿色精细化反应革新技术3) 晶型专利规避和晶型控制革新技术名优产品1）眼科原料药：地夸磷索钠、盐酸丙美卡因、立他司特、普拉洛芬、盐酸氮䓬斯汀、溴芬酸钠；2）特色原料药：阿伐那非、氯贝酸铝、米拉贝隆、盐酸丁卡因、羧甲司坦、更昔洛韦。设施情况多功能生产线（1、2线）：26台反应釜（适合1kg至100kg批量）；20L加氢反应釜；超/纳滤层析生产线；精烘包车间（带蒸汽干燥）；超微粉碎（3-5kg/h，＜10μm）。大盘冻干生产线（3线）：C级大盘冻干普药原料药生产线，可满足原辅料生产，300L容积。核苷车间（4线）：树脂纯化生产线860㎡；反应釜500-5000L，9台。联系我们如有业务需求，欢迎联系。王欢 13588474548

一致性评价创新药

100 项与氯贝酸铝相关的药物交易

登录后查看更多信息